INTERVIEW: Lupin head on US plans, fair biosimilar pricing and 'letting go'
This article was originally published in Scrip
Executive Summary
For those who've interacted with Lupin's founder chairman Dr Desh Bandu Gupta, his son Nilesh, who took over as managing director of the Indian pharma firm in September, is perhaps quite a contrast. Not that Dr Gupta ever held back, but Mr Gupta junior clearly represents India's young, ambitious and plain-speaking bosses, who are able to discuss both their company's successes and challenges, including some personal ones, with the same relative ease.